BeyondSpring Inc. Announces Upcoming Presentations at Major Conferences

Exciting News for Cancer Patients

FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, has some groundbreaking updates to share. The Company will be presenting final efficacy data on the combination of Plinabulin and docetaxel versus docetaxel alone in EGFR wild-type 2L/3L non-small cell lung cancer (NSCLC) at the 2024 World Conference on Lung Cancer in San Diego, CA on September 9, 2024.

Leading the Way in Cancer Research

In addition to this oral presentation, BeyondSpring will also be showcasing two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain on September 14, 2024. These presentations will focus on the safety outcomes of the Dublin-3 study and the results of the 303 Study, an investigator-initiated study supported by Merck.

Impact on Individuals

For cancer patients, this news represents a glimmer of hope. The data presented at these conferences could potentially lead to new and more effective treatment options for those battling NSCLC. BeyondSpring’s dedication to developing innovative therapies is a promising sign for the future of cancer treatment.

Global Impact

On a larger scale, BeyondSpring’s research and presentations have the potential to impact the field of oncology as a whole. The data shared at these major conferences could pave the way for advancements in cancer research and treatment that benefit individuals worldwide.

Conclusion

Overall, BeyondSpring’s upcoming presentations at the 2024 World Conference on Lung Cancer and the ESMO Congress 2024 are a significant milestone for the Company and the field of cancer research. The potential implications of the data shared could be life-changing for cancer patients and have a lasting impact on the global fight against cancer.